Clinical Trial

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-22.
Trial Details
NCT Number NCT07084896
Lead Sponsor GlaxoSmithKline
Conditions Multiple Myeloma
Enrollment 106 participants
Start Date 2020-06-08
Primary Completion 2025-04-17 (estimated)
Study Completion 2027-03-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-06